I

ITF Therapeutics

Develops and commercializes rare-disease therapies

Director – Patient Advocacy - Inherited Metabolic Disorders

Community Outreach & ProgramsConfirmed live in the last 24 hours
Full-timeRemote in USA$225k - $245k

About the Job

Requirements

  • A bachelor's degree is required.
  • At least 8 years of experience in patient advocacy, patient engagement, public affairs, healthcare, rare disease, or a related field, including experience developing and executing advocacy strategies.
  • Ability to build and sustain trusted partnerships with patient advocacy organizations, community leaders, and other external stakeholders.
  • Strategic thinking and business acumen, including experience translating patient and caregiver insights into actionable organizational strategies.
  • Communication, presentation, and stakeholder management skills, with the ability to influence across all levels of an organization.
  • Experience leading cross-functional initiatives and working effectively across Medical Affairs, Clinical Development, Commercial, Market Access, and Regulatory teams.
  • Knowledge of healthcare compliance requirements and industry regulations governing interactions with patient advocacy organizations.

Responsibilities

  • Develop and execute the U.S. IMD patient advocacy strategy, ensuring alignment with organizational priorities, business objectives, and the evolving needs of the IMD community.
  • Build, cultivate, and maintain trusted relationships with national, regional, and local patient advocacy organizations, community leaders, caregivers, and individuals living with IMD.
  • Serve as the primary patient advocacy lead for U.S. IMD, providing strategic guidance and representing the patient perspective across cross-functional teams, including medical affairs, commercial, market access, and regulatory functions.
  • Identify, gather, and translate community insights into actionable recommendations that inform decision-making across the product lifecycle.
  • Lead the development and execution of patient engagement initiatives that elevate patient and caregiver voices and foster meaningful collaboration with the IMD community.
  • Partner with internal stakeholders to ensure patient advocacy strategies are integrated into evidence generation activities, educational initiatives, policy efforts, and commercialization strategies.
  • Monitor the external advocacy, healthcare, and policy landscape to identify emerging trends, unmet needs, opportunities, and potential risks impacting the IMD community.
  • Support the design and implementation of patient-focused research, advisory boards, community listening initiatives, and other programs that generate meaningful patient insights.
  • Ensure all patient advocacy activities are conducted in accordance with applicable legal, regulatory, compliance, and industry guidelines.
  • Represent the organization at patient advocacy meetings, scientific congresses, community events, and industry forums to strengthen partnerships and advance shared goals.
  • Establish and monitor key performance indicators to measure the effectiveness and impact of patient advocacy initiatives and partnerships.

Desired Qualifications

  • An advanced degree in public health, healthcare, life sciences, public policy, communications, or a related field.
  • Experience supporting rare disease, genetic disease, lysosomal storage disorder, or MPS-focused programs and communities.
  • Strong understanding of the drug development lifecycle and opportunities for patient engagement from early research through commercialization.
  • Existing relationships within the rare disease and patient advocacy community.
  • Experience designing and implementing patient insight generation activities, including advisory boards, community listening sessions, and patient-focused research.
  • Experience working within a global or matrixed biopharmaceutical organization.
  • Demonstrated success in advancing patient-centered initiatives that influence policy, research, access, or care for rare disease communities.

About the Company

ITF Therapeutics

Develops and commercializes rare-disease therapies

ITF Therapeutics is a division of Italfarmaco S.p.A. focused on developing and commercializing treatments for rare diseases in the U.S., especially Duchenne Muscular Dystrophy (DMD). The company works on early-stage research and clinical development, partnering with patient advocacy groups and clinical leaders to align programs with patient needs. Its lead program is DUVYZAT (givinostat), a histone deacetylase (HDAC) inhibitor aimed at DMD. Revenue comes from bringing these specialized therapies to market. Compared with competitors, ITF Therapeutics emphasizes collaboration with patient groups and clinicians, a pipeline-focused early-development approach, and a specialty in HDAC inhibitors for rare diseases. The company’s goal is to deliver effective treatments for rare-disease patients by advancing promising therapies through development and into commercialization.

Company size
1-10
Company stage
Not listed
Total funding
Not listed
Headquarters
Concord, NH
Founded
2024

Recently Posted Jobs

Explore more opportunities at ITF Therapeutics

See more jobs